Allogeneic Hematopoietic Stem Cell Transplant for an Unknown Inherited Bone Marrow Failure Syndrome With a Novel Compound Heterozygous Mutation
Olayinka Okeleji(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Priti Tewari(The University of Texas MD Anderson Cancer Center), Sajad Khazal(The University of Texas MD Anderson Cancer Center), Kris M. Mahadeo(Duke University), Jeremy Connors(The University of Texas MD Anderson Cancer Center), Dristhi Ragoonanan(The University of Texas MD Anderson Cancer Center), Courtney D. DiNardo(The University of Texas MD Anderson Cancer Center), Demetrios Petropoulos(The University of Texas MD Anderson Cancer Center), Nidra Rodriguez(Memorial Hermann)
Cited by 0
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k